<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Anc Sci Life</journal-id><journal-id journal-id-type="iso-abbrev">Anc Sci Life</journal-id><journal-id journal-id-type="publisher-id">ASL</journal-id><journal-title-group><journal-title>Ancient Science of Life</journal-title></journal-title-group><issn pub-type="ppub">0257-7941</issn><issn pub-type="epub">2249-9547</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3800873</article-id><article-id pub-id-type="publisher-id">ASL-32-119</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>PA01.69. Immunological and virological effect of amrita tablate in human immunodeficiency virus positive patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mishra</surname><given-names>Brajeshwar</given-names><suffix>Dr.</suffix></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><collab><italic>From</italic> 5th World Ayurveda Congress 2012 Bhopal, Madhya Pradesh, India. 7-10 Dec 2012</collab><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff id="aff1"><label>1</label>Indian Drug Research Institute, Motihari, East Champaran, Bihar</aff><aff id="aff2"/><pub-date pub-type="ppub"><month>12</month><year>2012</year></pub-date><volume>32</volume><issue>Suppl 1</issue><fpage>S119</fpage><lpage>S119</lpage><permissions><copyright-statement>Copyright: &#x000a9; 2012 Brajeshwar Mishra; licensee Ancient Science of Life.</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</uri>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Purpose:</title><p>To assess the safety and efficacy of Amrita tablets in human immunodeficiency virus positive patients.</p></sec><sec id="st2"><title>Method:</title><p>The randomized double blind placebo controlled trial carried out 40 HIV positive patients at Ayurvedic Drug Research Institute Motihari Bihar, with permission from Institutional Ethic Committee for achieve the purpose. Out of 40 HIV patients 30 were male and 10 patients of female. The HIV positive patients were randomly assigned to three groups A, B and C. Group A received Amrita tablet. Group B received Amritasava and group C received Placebo. The doses of Amrita tablet, two tabs. And Amritasava 10ml with one cup water twice daily for six months. The hematological investigation was repeated at the end of the study.</p></sec><sec id="st3"><title>Result:</title><p>In study participants, HIV was more common in the 15 30 year's age group. Half of the enrolled patients where from the age group 42% from 30 40 years and 8% from 40 50 age group. It was observed the end of trial period of amrita tablet was marked increase in the number of CD4count and viral load reduced&#x0003c;300 copies/ml. It was also found gradual reduction of clinical feature of early symptomatic stage of HIV disease. Among the participants received Amritasava there was moderate increase in the number of CD4 count, but there was no difference in viral load. Participants was received placebo there was no differences in CD4 count before the six months.</p></sec><sec id="st4"><title>Conclusion:</title><p>Amrita tab. is an ideal herbal formulation. It contain mainly standardchemically defined Asava of Amrita (Tinospora cardifolia) ashwagandha (Withania somnifera) and yasthimadhu (Glycyrrhiza glabra). It increases in number of CD4 count and reduce viral load. It is safe and no adverse toxic effect on long therapy. Now it is necessary to evaluate the physiological activity, pharmacological property toxicity and determination of structure of amrita tab. To antiretroviral classes of drug for used in the health care systems of countries with in the Region and elsewhere in the world.</p></sec></abstract></article-meta></front></article>